Consonance Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Consonance Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-432,787	Closed	-$123M	–	33
2020 Q2	$123M	Sell	432,787 -45,926	-10%	-$13.6M	7.37%	2
2020 Q1	$138M	Buy	478,713 +70,217	+17%	+$19.4M	10.27%	1
2019 Q4	$117M	Buy	408,496 +19,334	+5%	+$4.19M	7.17%	3
2019 Q3	$56.2M	Buy	389,162 +2,280	+0.6%	+$309K	5.56%	7
2019 Q2	$34.8M	Buy	386,882 +42,956	+12%	+$3.45M	2.46%	15
2019 Q1	$30.1M	Buy	343,926 +23,254	+7%	+$2.58M	1.9%	17
2018 Q4	$45.1M	Sell	320,672 -1,133	-0.4%	-$191K	3.31%	13
2018 Q3	$82.2M	Buy	321,805 +4,000	+1%	+$1.11M	4.43%	8
2018 Q2	$81M	Buy	+317,805	New	+$78.6M	5.22%	6

Other funds holding KPTI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Consonance Capital Management's KPTI Position: Q3 2020 in Review

Consonance Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2020, closing a stake of 432,787 shares — an estimated $123M sold.

Consonance Capital Management first reported a position in KPTI in Q2 2018 and held it in 9 quarters. The position peaked at $138M in Q1 2020. 157 funds tracked by Wall St. Rank hold KPTI as of Q3 2020.

Consonance Capital Management reported no remaining Karyopharm Therapeutics position as of Q3 2020 after selling out during the quarter.
Consonance Capital Management sold 432,787 Karyopharm Therapeutics shares in Q3 2020, an estimated $123M.
Consonance Capital Management first reported a position in Karyopharm Therapeutics in Q2 2018 and held it in 9 quarters.
Consonance Capital Management's Karyopharm Therapeutics position peaked at $138M in Q1 2020.
157 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2020.

Based on Consonance Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.